SEARCH

SEARCH BY CITATION

References

References

  • 1
    Reshef A, Moldovan D, Obtulowicz K, Leibovich I, Mihaly E, Visscher S et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy 2013;68:118124.
  • 2
    Craig T, Riedl M, Dykewicz MS, Gower RG, Baker J, Edelman FJ et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 2009;102:366372.
  • 3
    Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B et al. 2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angio-oedema. Allergy Asthma Clin Immunol 2010;6:2437.
  • 4
    Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67:147157.
  • 5
    Bork K, Hardt J. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Medicine 2009;122:780783.
  • 6
    Plosker GL. Recombinant human C1 inhibitor (Conestat Alfa) in the treatment of angioedema attacks in hereditary angioedema. Biodrugs 2012;26:315323.
  • 7
    Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010;31:407414.